Linagliptin
Dipeptidyl Peptidase 4 (Dpp-4) Inhibitors
Sold as TRAJENTA · JENTADUETO
- Drug class
- Dipeptidyl Peptidase 4 (Dpp-4) Inhibitors
- Availability
- See label
- Routes
- Oral
- Markets covered
- 3
- Products on record
- 120
Overview
Linagliptin is an active pharmaceutical ingredient in the Dipeptidyl Peptidase 4 (Dpp-4) Inhibitors group (A10BH). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 114 | May 29, 2026 |
| CA Canada | Health Canada | 4 | March 22, 2025 |
| EU European Union | EMA | 2 | February 12, 2026 |
GBUnited Kingdom· MHRA
114 products
Uses
Linagliptin 5mg Film-coated tablets is indicated in adults with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control as: monotherapy • when metformin is inappropriate due to intolerance, or contraindicated due to renal impairment.
1 for available data on different combinations).
How to take
CACanada· Health Canada
4 products
Uses
AND CLINICAL USE ........................................................................ 3 CONTRAINDICATIONS ............................................................................................. 4 WARNINGS AND PRECAUTIONS ............................................................................
5 ADVERSE REACTIONS ............................................................................................ 15 DRUG INTERACTIONS ............................................................................................ 26 DOSAGE AND ADMINISTRATION ........................................................................
31 OVERDOSAGE........................................................................................................... 33 ACTION AND CLINICAL PHARMACOLOGY ...................................................... 34 STORAGE AND STABILITY ....................................................................................
EUEuropean Union· EMA
2 products
Uses
Jentadueto is indicated in adults with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control: • in patients inadequately controlled on their maximally tolerated dose of metformin alone • in combination with other medicinal products for the treatment of diabetes, including insulin, in patients inadequately controlled with metformin and these medicinal products • in patients already being treated with the combination of linagliptin and metformin as separate tablets.
1 for available data on different combinations).
How to take
Drug interactions
Known interactions involving Linagliptin. Select one for details. This list is informational and not a complete interaction checker.
Showing 240 of 260. Type above to find a specific drug.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PL218800353 · revised August 6, 2025
- [2]Health Canada (DPD) · 02403250 · revised March 22, 2025
- [3]European Medicines Agency · EMEA/H/C/002279 · revised February 12, 2026
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.